ASH Annual Meeting and Exposition | Conference

Dr. Neelapu on Interim Results of the Phase II ZUMA-1 Study in DLBCL

December 29th 2016

Sattva S. Neelapu, MD, associate professor, Department of Lymphoma/Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses interim results of the phase II ZUMA-1 study in patients with diffuse large B-cell lymphoma.

Dr. Daver on Immune Checkpoint Pathways in AML

December 28th 2016

Naval Daver, MD, assistant professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses research evaluating different immune checkpoint pathways in patients with acute myeloid leukemia.

Lenalidomide Shows Activity in Low-Risk MDS

December 22nd 2016

Results from the randomized phase II HOVON89 trial showed that nearly 40% of patients with low intermediate-1 risk myelodysplastic syndrome who were refractory to erythropoietin and granulocyte-colony stimulating factor experienced hematologic improvement with erythroid response after being treated with lenalidomide monotherapy.

Dr. Perales on the PROGRESS II Trial in Hematologic Malignancies

December 22nd 2016

Miguel-Angel Perales, MD, deputy chief, Adult Bone Marrow Transplant Service, director, Adult Bone Marrow Transplantation Fellowship Program, Memorial Sloan Kettering Cancer Center, provides an overview of the PROGRESS II trial, which was conducted for patients with hematologic malignancies.

Dr. Jones on the Efficacy of Venetoclax in Relapsed/Refractory CLL

December 22nd 2016

Jeffrey Jones, MD, MPH, assistant professor of Internal Medicine, Division of Hematology, The Ohio State University, discusses the results of a phase II study that evaluated the efficacy of venetoclax in the treatment of patients with chronic lymphocytic leukemia whose disease had progressed after treatment with either ibrutinib or idelalisib.

Venetoclax Active in Heavily Treated Multiple Myeloma

December 21st 2016

The BCL-2 inhibitor venetoclax (Venclexta) demonstrated activity in one-fifth of patients with heavily pretreated multiple myeloma.

Dr. Takahashi on Biomarker That Predicts Development of Therapy-Related Leukemia

December 21st 2016

Koichi Takahashi, MD, assistant professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses a study exploring a potential biomarker for patients likely to develop therapy-related leukemia.

Benefits of Daratumumab Triplets in Myeloma Sustained With Longer Follow-Up

December 20th 2016

The benefits of 2 FDA-approved daratumumab–based triplet regimens were sustained in long-term data from 2 pivotal phase III studies presented at the 2016 ASH Annual Meeting.

Entospletinib Shows Modest Activity in Mantle Cell Lymphoma

December 20th 2016

Entospletinib was well tolerated and demonstrated modest activity in patients with relapsed or refractory mantle cell lymphoma.

High Rates of Symptoms, Impairment, With Myeloproliferative Neoplasms

December 20th 2016

Patients with myeloproliferative disorders have a high symptom burden that significantly affects emotional status, quality of life, and functional ability.

Ruxolitinib Demonstrates Consistent Survival Benefit in Myelofibrosis

December 19th 2016

Patients with intermediate/high-risk myelofibrosis had improved survival when treated long term with the Janus kinase inhibitor ruxolitinib.

Novel Agent Slows High-Risk Myelofibrosis in Initial Trial

December 19th 2016

A third of patients with previously treated, high- and intermediate-risk myelofibrosis had objective responses to the investigational Second mitochondria-derived activator of caspases mimetic LCL161.

Gene Expression Studies Offer Insight Into Myeloma Regimen's Efficacy

December 19th 2016

An analysis of c-MYC expression in relapsed myeloma identified subgroups of patients with improved response to the combination of an immunomodulator and a proteasome inhibitor.

Dual Transplant Prevails in Patients With Newly Diagnosed Myeloma

December 19th 2016

Patients with newly diagnosed multiple myeloma had significant improvement in progression-free survival when treated with dual versus single autologous stem-cell transplant.

Expanded Access Data Confirm Safety, Efficacy of Ruxolitinib in Myelofibrosis

December 16th 2016

Worldwide clinical experience with the JAK1/2 inhibitor ruxolitinib (Jakafi) in patients with myelofibrosis has yielded safety and efficacy data similar to results of a pivotal randomized trial.

Addition of Daratumumab Triples Increase in MRD Conversion in Relapsed Myeloma

December 16th 2016

The addition of daratumumab to standard-of-care regimens tripled the increase in conversion to negative minimal residual disease status in the treatment of patients with relapsed/refractory multiple myeloma.

Elotuzumab Triplet Yields High Response Rate in High-Risk Smoldering MM

December 12th 2016

The combination of elotuzumab, lenalidomide, and dexamethasone has excellent activity and is well-tolerated in the treatment of high-risk smoldering multiple myeloma (SMM), providing hope that it can delay or even halt progression to MM.

More Randomized Data Support Pacritinib Efficacy in Myelofibrosis

December 8th 2016

Patients with myelofibrosis and thrombocytopenia had significantly greater reductions in spleen volume and symptoms when treated with the multikinase inhibitor pacritinib, compared with the best available therapy.

JCAR017 Shows Promising Activity, Mild Toxicity in CD19+ Lymphoma

December 8th 2016

The CD19-directed CAR T-cell therapy JCAR017 demonstrated a 60% complete response rate in patients with relapsed or refractory CD19-positive non-Hodgkin lymphoma.

Multiple Myeloma Transplant Trial Shows No Extra Benefit with Additions to Standard Therapy

December 8th 2016

According to the results of the phase III StaMINA trial evaluating posttransplant therapy in multiple myeloma, a second a round of chemotherapy or stem cell transplant does not improve progression-free survival or overall survival compared with the current standard course of treatment alone.